Abstract
Objective Assess characteristics of clinical pneumonia after introduction of pneumococcal conjugate vaccine (PCV), by HIV exposure status, in children hospitalized in a governmental hospital in Malawi.
Methods and findings We evaluated 1,139 children ≤5 years old hospitalised with clinical pneumonia: 101 HIV-exposed uninfected (HEU) and 1038 HIV-unexposed, uninfected (HUU). Median age was 11 months (IQR 6-20), 59% were male, median mid-upper arm circumference (MUAC) was 14 cm (IQR 13-15) and mean weight-for-height z score was -0.7 (±2.5). The highest Respiratory Index of Severity in Children (RISC) scores were allocated to 10.4% of the overall cohort, respectively. Only 45.7% had fever, and 37.2% had at least one danger sign at presentation. The most common clinical features were crackles (54.7%), nasal flaring (53.5%), and lower chest wall indrawing (53.2%). Compared to HUU, HEU children were significantly younger (9 months v. 11 months), with lower mean birth weight (2.8 kg v. 3.0 kg) and MUAC (13.6 cm v. 14.0 cm), had higher prevalence of vomiting (32.7% v. 22.0%), tachypnoea (68.4% v. 49.8%), and highest RISC scores (20.0% v. 9.4%). Five children died (0.4%). However, clinical outcomes were similar for both groups.
Conclusions In this post-PCV setting where prevalence of HIV and malnutrition is high, children hospitalised fulfilling the WHO Integrated Management of Childhood Illness criteria for clinical pneumonia present with heterogeneous features. These vary by HIV exposure status but this does not influence either the frequency of danger signs or mortality. The poor performance of available severity scores in this population and the absence of more specific diagnostics hinder appropriate antimicrobial stewardship and the rational application of other interventions.
Strengths and limitations of the study
We evaluated over 1,100 children hospitalized with pneumonia in a low-income country setting after introduction of PCV.
This observational cohort was nested within a prospective hospital-based study of PCV13 effectiveness
We assessed the demographic and clinical characteristics of clinical pneumonia patients and compared HEU vs. HUU children, and computed RISC scores for severe pneumonia
Competing Interest Statement
PI has received investigator-initiated research grant support from Bill & Melinda Gates Foundation outside the scope of this work; NAC has received research grant support and honoraria for participation in rotavirus vaccine advisory board meetings from GlaxoSmithKline Biologicals and from Takeda Pharmaceuticals outside the scope of this work; NF has received investigator-initiated research grant support from GlaxoSmithKline Biologicals and from Takeda Pharmaceuticals outside the scope of this work. NBZ has received investigator-initiated research grant support from GlaxoSmithKline Biologicals, Takeda Pharmaceuticals, Merck-Sharpe-Dohme and the Serum Institute of India, all outside the scope of this work. All other authors declare that they have no financial disclosures.
Funding Statement
This work was supported by a Wellcome Trust Programme Grant (Grant number 091909/Z/10/Z) and the MLW Programme Core Award (Grant 206454) from the Wellcome Trust.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the University of Malawi College of Medicine Research Ethics Committee (P.05/13/1386) and by the University of Liverpool (RETH490).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Abbreviations
- CI
- confidence interval
- CPAP
- continuous positive airway pressure
- HEU
- HIV-exposed, uninfected
- HUU
- HIV-unexposed, uninfected
- IMCI
- integrated management of childhood illness
- IQR
- interquartile range
- mRISC
- modified respiratory index of severity in children
- MUAC
- mid-upper arm circumference
- PCV13
- 13-valent pneumococcal conjugate vaccine
- ResViNet
- Respiratory Syncytial Virus Network
- RISC
- respiratory index of severity in children
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos